Suchen
Valneva SE
VALNZur Watchlist hinzufügen
5.225USD
+0.135+2.65%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
453.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Valneva SE Unternehmen
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE Informationen
BörsenkürzelVALN
Name des UnternehmensValneva SE
IPO-datumJun 28, 2007
CEOLingelbach (Thomas)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJun 28
Addresse6, Rue Alain Bombard
StadtSAINT-HERBLAIN
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl44800
Telefon33228073710
Websitehttps://valneva.com/
BörsenkürzelVALN
IPO-datumJun 28, 2007
CEOLingelbach (Thomas)
Führungskräfte von Valneva SE
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Valneva SE?
Die fünf größten Anteilseigner von Valneva SE sind: Mr. Franck Grimaud
Wie viele Institutionen halten Anteile an Valneva SE (VALN)?
Mit Stand vom 2026Q1 halten 36 Institutionen Anteile an Valneva SE, mit einem Gesamtmarktwert von etwa 5.21M, was 5.50% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -309162.00 gestiegen.
Was ist die größte Einnahmequelle von Valneva SE?
Am 2026Q1 erzielte das Geschäft mit IXIARO für Valneva SE den höchsten Umsatz in Höhe von 98.42M, was 56.35% des Gesamtumsatzes entspricht.